<i>Egr1</i> Gene Expression as a Potential Biomarker for In Vitro Prediction of Ocular Toxicity

• Main Authors: Da-Bin Hwang (Author), Shin-Young Kim (Author), Dong-Hoon Won (Author), Changuk Kim (Author), Yoo-Sub Shin (Author), Jong-Hwan Park (Author), Young-Jin Chun (Author), Kyung-Min Lim (Author), Jun-Won Yun (Author)
• Format: Book
• Published: MDPI AG, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Animal models are used for preclinical toxicity studies, and the need for in vitro alternative methods has been strongly raised. Our study aims to elucidate the potential mechanism of change in EGR1 expression under situations of toxic injury and to develop an <i>Egr1</i> promoter-luciferase gene reporter assay for an in vitro alternative method for toxicity prediction in drug discovery. We first found an increase in early growth response-1 (EGR1) mRNA/protein expressions in the liver and kidney of cisplatin-treated injured rats. Additionally, the EGR1 protein level was also elevated under situations of ocular injury after sodium lauryl sulfate (SLS) eye drops. These in vivo observations on injury-related EGR1 induction were confirmed by in vitro studies, where human corneal epithelial cells were treated with representative irritants (SLS and benzalkonium chloride) and 17 chemicals having different UN GHS irritant categories. Additionally, our results suggest the involvement of ERK, JNK, p38 MAPK pathways in EGR1 elevation in response to gamma-butyrolactone-induced injury. As EGR1 is considered to be a pivotal factor in proliferation and regeneration, siRNA-mediated knockdown of <i>Egr1</i> promoted cytotoxic potential through a delay of injury-related recovery. More importantly, the elevation of promoter activities was observed by various irritants in cells transfected with <i>Egr1</i> promoter-reporter vector. In conclusion, <i>Egr1</i> can be a potential biomarker in a promoter-reporter system to improve the accuracy of in vitro predictions for ocular irritation.

Item Description

10.3390/pharmaceutics13101584
1999-4923